Table 1.
Clinical and laboratory characteristics in cases and controls.
| Parameters | HCV cases (N = 63) | Controls (N = 63) | P |
|---|---|---|---|
| Age (year) | 60.9 ± 10.5 | 60.8 ± 10.5 | 0.93 |
| Gender (male) | 41 (65.1) | 41 (65.1) | 1 |
| Race | |||
| White | 35 (55.6) | 35 (55.6) | 1 |
| AA | 18 (28.6) | 17 (27) | 0.84 |
| Hispanic | 3 (4.8) | 4 (6.3) | 1 |
| Asian | 7 (11.1) | 7 (11.1) | 1 |
| BMI | 32.2 ± 13.5 | 29.8 ± 6.1 | 0.51 |
| DM | 28 (44.4) | 26 (41.3) | 0.72 |
| Hypertension | 52 (82.5) | 51 (81) | 0.81 |
| Hyperlipidemia | 33 (52.4) | 43 (68.4) | 0.06 |
| Tobacco use | 29 (46) | 26 (41.3) | 0.59 |
| Alcohol abuse | 8 (12.7) | 10 (15.9) | 0.61 |
| Family history of CAD | 21 (33.3) | 28 (44.4) | 0.20 |
| IVDU | 3 (4.8) | 3 (4.8) | 1 |
| SBP (mm Hg) | 138 ± 26 | 140 ± 23 | 0.52 |
| DBP (mm Hg) | 77 ± 13 | 81 ± 12 | 0.14 |
| LDL (mg/dL) | 91 ± 30 | 88 ± 35 | 0.46 |
| HDL (mg/dL) | 42 ± 21 | 42 ± 12 | 0.56 |
| Cholesterol (mg/dL) | 147 ± 40 | 144 ± 43 | 0.59 |
| Triglyceride (mg/dL) | 125 ± 68 | 102 ± 78 | 0.02 |
| ALT IU/L | 51 ± 41 | 43 ± 63 | 0.01 |
| Hb (%) | 12.2 ± 1.9 | 13.1 ± 1.8 | 0.01 |
| Aspirin | 31 (49.2) | 43 (68.3) | 0.03 |
| Beta blocker | 29 (46) | 37 (58.7) | 0.15 |
| ACE inhibitors | 30 (47.6) | 32 (50.8) | 0.72 |
| Ca++ channel blocker | 8 (12.7) | 10 (15.9) | 0.54 |
| Statin | 26 (41.3) | 44 (70) | 0.001 |
AA, African American; BMI, body mass index; DM, diabetes mellitus; CAD, coronary artery disease; IVDU, intravenous drug use; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; ALT, alanine aminotransferases.